Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice

Sato, Ayumi; Takagi, Motoki; Shimamoto, Akira; Kawakami, Shigeru; Hashida, Mitsuru

doi:10.1016/j.biomaterials.2006.11.010

Cited by 119 publications

(77 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, the level of IFN-gamma was not detectable when delivering R8-modified lipid nanoparticles. This phenomenon is very surprising because the production of IFN-gamma is usually detected on the intravenous injection of liposome/siRNA complex (Sato A et al, 2007) or siRNA encapsulated nanoparticles (Zimmermann TS et al, 2006). These observations suggest that siRNA may be safer than pDNA even when the cationic nanoparticle systems without PEG modification are used and R8-modified lipid nanoparticles may be tolerated by the immune response.…”

Section: Discussionmentioning

confidence: 99%

Cell penetrating peptide-mediated systemic siRNA delivery to the liver

Hayashi

Yamauchi

Khalil

et al. 2011

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Footnote:Yasuhiro Hayashi and Jun Yamauchi equally contributed to this study. These authors are listed alphabetically in accordance with family name. AbstractThe Cell-penetrating peptide (CPP) is one of the most attractive tools for efficiently delivering biomolecules to a target organnelle. Here, we describe the use of octaarginine (R8)-modified lipid nanoparticles for the efficient and targeted in vivo delivery of siRNA to the liver. In this study, SR-BI (a scavenger receptor class B, member 1) was targeted by this nanoparticle. Our results demonstrate that R8-modified lipid nanoparticles can be used for the efficient and targeted delivery of liver siRNA to induce the specific knock-down of an endogenous gene with minimum liver toxicity and immune response, and that this CPP based technology holds considerable promise for further in vivo biological applications of siRNA.

show abstract

Section: Discussionmentioning

confidence: 99%

Cell penetrating peptide-mediated systemic siRNA delivery to the liver

Hayashi

Yamauchi

Khalil

et al. 2011

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…An effective delivery system is essential for the application of siRNA as clinical treatment. Our previous study demonstrated that a siRNA (Ubc-13)/galactosylated cationic liposomes complex was efficiently delivered to hepatocytes [171]. Sonoke et al also reported the hepatocyte-selective delivery of siRNA (firefly luciferase) using siRNA/galactosylated cationic liposomes complexes [172].…”

Section: Nucleic Acid Deliverymentioning

confidence: 98%

Glycosylation-mediated targeting of carriers

Kawakami

Hashida

2014

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

For safe and effective therapy, drugs should be delivered selectively to their target tissues or cells at an optimal rate. Drug delivery system technology maximizes the therapeutic efficacy and minimizes unfavorable drug actions by controlling their distribution profiles. Ligand-receptor binding is a typical example of specific recognition mechanisms in the body; therefore, ligand-modified drug carriers have been developed for active targeting based on receptor-mediated endocytosis. Among the various ligands reported thus far, sugar recognition is a promising approach for active targeting because of their high affinity and expression. Glycosylation has been applied for both macromolecular and liposomal carriers for cell-selective drug targeting.Recently, the combination of ultrasound exposure and glycosylated bubble liposomes has been developed. In this review, recent advances of glycosylation-mediated targeted drug delivery systems are discussed.

show abstract

“…The asialoglycoprotein receptor is expressed on hepatocytes and is able to recognise the galactose units on the oligosaccharide chains of glycoproteins or on chemically synthesised galactosylated carriers [81,82] .…”

Section: Serum Stabilitymentioning

confidence: 99%

“…For example, systemic administration of such complexes was directed specifically towards liver parenchymal cells and produced a knockdown of the endogenous gene Ubc13 [81] . In the treatment of hepatitis C (HCV) it is essential that any treatment is specifically targeted to the liver.…”

Section: Serum Stabilitymentioning

confidence: 99%

Therapeutic targeting in the silent era: advances in non-viral siRNA delivery

et al. 2010

View full text Add to dashboard Cite

Access to the full text of the published version may require a subscription. Rights AbstractGene silencing using RNA-interference, first described in mammalian systems almost a decade ago, is revolutionizing therapeutic target validation efforts both in vitro and in vivo. Moreover, the potential for using short interfering RNA (siRNA) as a therapy in its own right is also progressing at a significant pace. However, the widespread use of such approaches is contingent on having appropriate delivery systems to achieve clinically appropriate, safe, and efficient delivery of siRNA. There are many physicochemical and biological barriers to such delivery, and a growing emphasis on the design and characterisation of non-viral technologies that will overcome these barriers and expedite targeted delivery. This review discusses the considerations and challenges associated with use of siRNA-based therapeutics, including stability and off-target effects. Speculation is made on the properties of an ideal delivery system and the non-viral delivery approaches used to date, both in vitro and in vivo, are classified and discussed. Moreover, the ability of cyclodextrin-based delivery vectors to fulfil many of the criteria of an ideal delivery construct is also elaborated.3 Introduction:

show abstract

Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice

Cited by 119 publications

References 28 publications

Cell penetrating peptide-mediated systemic siRNA delivery to the liver

Cell penetrating peptide-mediated systemic siRNA delivery to the liver

Glycosylation-mediated targeting of carriers

Therapeutic targeting in the silent era: advances in non-viral siRNA delivery

Contact Info

Product

Resources

About